<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cromolyn (sodium cromoglicate) (systemic): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cromolyn (sodium cromoglicate) (systemic): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Cromolyn (sodium cromoglicate) (systemic): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="104681" href="/d/html/104681.html" rel="external">see "Cromolyn (sodium cromoglicate) (systemic): Drug information"</a> and <a class="drug drug_patient" data-topicid="104682" href="/d/html/104682.html" rel="external">see "Cromolyn (sodium cromoglicate) (systemic): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F44942107"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Gastrocrom</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F56680528"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Nalcrom</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F45116740"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Mast Cell Stabilizer</span></li></ul></div>
<div class="block dop drugH1Div" id="F44942152"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c5b5f2da-abcc-4c4e-aeaf-6cd1d41eb92d">Systemic mastocytosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Systemic mastocytosis:</b> Oral solution:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> In patients &lt;2 years of age, routine use not recommended; in this age group, reserve for patients with severe disease in whom potential benefits outweigh risks.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants &lt;6 months: Limited data available: Oral: Initial: 20 mg/kg/<b>day</b> in 4 divided doses; maximum daily dose: 20 mg/kg/<b>day</b>. Once desired effect is achieved, dose may be tapered to lowest effective maintenance dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥6 months and Children &lt;2 years: Limited data available: Oral: Initial: 20 mg/kg/<b>day</b> in 4 divided doses; maximum dose: 100 mg/dose; if control of symptoms is not observed within 2 to 3 weeks, may increase dose; maximum daily dose: 40 mg/kg/<b>day</b>. Once desired effect is achieved, dose may be tapered to lowest effective maintenance dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥2 years: Oral: Initial: 100 mg 4 times daily; maximum daily dose: 40 mg/kg/<b>day</b>; once desired effect is achieved, dose may be tapered to lowest effective maintenance dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents: Oral: Initial: 200 mg 4 times daily; once desired effect is achieved, dose may be tapered to lowest effective maintenance dose.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0b6908ea-f599-4917-9a46-bdfd62ce5f83">Food allergy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Food allergy:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Canadian labeling: </i>Nalcrom capsule [Canadian product]:</p>
<p style="text-indent:-2em;margin-left:6em;">Treatment:</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥2 years and Adolescents ≤14 years: Oral: Initial: 100 mg 4 times daily; may double the dose if effect is not satisfactory within 2 to 3 weeks; maximum daily dose: 40 mg/kg/<b>day</b>; once the desired effect is achieved, dose may be tapered to lowest effective maintenance dose.</p>
<p style="text-indent:-2em;margin-left:8em;">Adolescents &gt;14 years: Oral: Initial: 200 mg 4 times daily; may double the dose if effect is not satisfactory within 2 to 3 weeks; maximum daily dose: 40 mg/kg/<b>day</b>; once the desired effect is achieved, dose may be tapered to lowest effective maintenance dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Prevention: <b>Note: </b>Recommended only for scenarios where the patient is not able to avoid allergenic foods (eg, school or restaurant meals).</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥2 years and Adolescents ≤14 years: Oral: 100 mg once; give 15 minutes before the meal.</p>
<p style="text-indent:-2em;margin-left:8em;">Adolescents &gt;14 years: Oral: 200 mg once; give 15 minutes before the meal.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51090058"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Children ≥2 years and Adolescents: Consider dose reduction; specific pediatric recommendations not available.</p></div>
<div class="block dohp drugH1Div" id="F51090059"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Children ≥2 years and Adolescents: Consider dose reduction; specific pediatric recommendations not available.</p></div>
<div class="block doa drugH1Div" id="F44942153"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="104681" href="/d/html/104681.html" rel="external">see "Cromolyn (sodium cromoglicate) (systemic): Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0b6908ea-f599-4917-9a46-bdfd62ce5f83">Food allergy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Food allergy:</b> Nalcrom [Canadian product]:</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Treatment: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Initial:</i>
<b>Oral:</b> 200 mg 4 times daily; dose may be doubled after 2 to 3 weeks if response not adequate to a maximum daily dose of 40 mg/kg/day.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Maintenance:</i>
<b> Oral:</b> Once therapeutic response is achieved, the dose may be reduced to the minimum required to maintain symptom control. The optimum dose required to maintain remission is individual, but it is likely not less than 200 mg 4 times daily.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Prevention: Patients unable to avoid allergenic foods under certain circumstances (ie, restaurants, school meals):</b>
<b>Oral:</b>
<i> Initial:</i> 200 mg administered 15 minutes before the meal. May adjust the dose to optimum dosage specific for each patient (maximum daily dose: 40 mg/kg/day).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b539615f-94ea-4a4e-9822-774e18624960">Mastocytosis, systemic or cutaneous</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Mastocytosis, systemic or cutaneous:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Initial:</i>
<b>Oral:</b> 200 mg (further diluted as an oral solution) 4 times daily; dose may be increased after 2 to 3 weeks if response not adequate to a maximum daily dose of 40 mg/kg/day.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Maintenance:</i>
<b>Oral: </b>Once therapeutic response is achieved, the dose may be reduced to the minimum required to maintain symptom control. Continue maintenance dosing to prevent relapses.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991685"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no specific dosage adjustments provided in the manufacturer’s labeling; however, a dose reduction is recommended (although systemic absorption following oral administration is &lt;1%).</p></div>
<div class="block doha drugH1Div" id="F50989008"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no specific dosage adjustments provided in the manufacturer’s labeling; however, a dose reduction is recommended (although systemic absorption following oral administration is &lt;1%).</p></div>
<div class="block adr drugH1Div" id="F44942128"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular: Chest pain, edema, flushing, palpitations, tachycardia, ventricular premature contractions</p>
<p style="text-indent:-2em;margin-left:2em;">Central nervous system: Headache (5%), irritability (2%), malaise (1%), anxiety, behavioral changes, burning sensation, convulsions, depression, dizziness, dizziness (postprandial), fatigue, hallucination, hypoesthesia, insomnia, lethargy, migraine, nervousness, paresthesia, psychosis</p>
<p style="text-indent:-2em;margin-left:2em;">Dermatologic: Pruritus (3%), skin rash (2%), erythema, skin photosensitivity, urticaria</p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal: Diarrhea (5%), nausea (3%), abdominal pain (2%), constipation, dyspepsia, dysphagia, esophageal spasm, flatulence, glossitis, stomatitis, unpleasant taste, vomiting</p>
<p style="text-indent:-2em;margin-left:2em;">Genitourinary: Dysuria, urinary frequency</p>
<p style="text-indent:-2em;margin-left:2em;">Hematologic &amp; oncologic: Neutropenia, pancytopenia, polycythemia, purpura</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic: Abnormal hepatic function tests</p>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity: Anaphylaxis, angioedema</p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular &amp; skeletal: Myalgia (3%), arthralgia, lower extremity weakness, lupus erythematosus, stiffness of legs</p>
<p style="text-indent:-2em;margin-left:2em;">Otic: Tinnitus</p>
<p style="text-indent:-2em;margin-left:2em;">Respiratory: Dyspnea, pharyngitis</p></div>
<div class="block coi drugH1Div" id="F44942125"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to cromolyn or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F44942126"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anaphylaxis: Severe anaphylactic reactions may occur rarely with use. In the event of anaphylaxis or an acute life-threatening hypersensitivity event (regardless of the trigger), cromolyn offers no benefit since it is has no antihistaminic, anti-inflammatory, or bronchodilator activity.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Disease-related concerns:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: The manufacturer’s labeling states to use with caution and adjust the dosage in patients with hepatic impairment, although systemic absorption following oral administration is &lt;1%.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: The manufacturer’s labeling states to use with caution and adjust the dosage in patients with renal impairment, although systemic absorption following oral administration is &lt;1%.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Withdrawal: Do not abruptly discontinue therapy when symptoms have been partially or completely controlled; use caution when withdrawing the drug or tapering the dose as symptoms may reoccur.</p></div>
<div class="block foc drugH1Div" id="F44942168"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Concentrate, Oral, as sodium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Gastrocrom: 100 mg/5 mL (5 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg/5 mL (5 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Concentrate, Oral, as sodium [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg/5 mL (5 mL)</p></div>
<div class="block geq drugH1Div" id="F44942111"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F44942170"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Concentrate</b> (Cromolyn Sodium Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg/5 mL (per mL): $0.24 - $1.50</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Concentrate</b> (Gastrocrom Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg/5 mL (per mL): $2.65</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F56680529"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral, as sodium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nalcrom: 100 mg</p></div>
<div class="block admp drugH1Div" id="F52614621"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral:</p>
<p style="text-indent:-2em;margin-left:2em;">Oral concentrate: Open ampul and squeeze contents into a glass of water; stir well; administer entire contents of glass at least 30 minutes before meals and at bedtime.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral capsule: Nalcrom [Canadian product]: Administer as a solution (preferred) by opening capsule contents into a cup and adding 5 mL of very hot water to dissolve; further dilute with 20 mL of cold water. May also swallow capsule whole. Administer 15 to 20 minutes before meals.</p></div>
<div class="block adm drugH1Div" id="F44942158"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Oral capsule: Nalcrom [Canadian product]: Administer as a solution (preferred) by opening the capsule and adding capsule contents to a cup with 5 mL of very hot water to dissolve, then further dilute with 20 mL of cold water. May also swallow capsule whole. Administer 15 to 20 minutes before meals.</p>
<p style="text-indent:-2em;margin-left:6em;">When using as a single preventative dose in situations where patients are unable to avoid allergenic foods (eg, restaurant), administer the dose 15 minutes prior to the meal.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral solution: Open ampule(s) and squeeze contents into glass of water; stir well; administer entire contents of glass on an empty stomach at least 30 minutes before meals and at bedtime.</p></div>
<div class="block sts drugH1Div" id="F44942139"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 15°C to 30°C (59°F to 86°F). Protect from light. Do not use oral solution if solution becomes discolored or forms a precipitate.</p></div>
<div class="block usep drugH1Div" id="F53571306"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Management of patients with mastocytosis (FDA approved in ages ≥2 years and adults); has also been used for management of food allergies.</p></div>
<div class="block cyt drugH1Div" id="F44942135"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F44942132"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F44942121"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events were not observed in animal reproduction studies. Systemic absorption following oral administration is &lt;1%.</p></div>
<div class="block pha drugH1Div" id="F44942142"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Prevents the mast cell release of histamine, leukotrienes, and slow-reacting substance of anaphylaxis by inhibiting degranulation after contact with antigens</p></div>
<div class="block phk drugH1Div" id="F44942144"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset: Response to treatment (mastocytosis): Oral: May occur within 2 to 6 weeks.</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: &lt;1% of dose absorbed.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 80 to 90 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine and feces (equal amounts as unchanged drug).</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-30961835">
<a name="30961835"></a>Castells M, Butterfield J. Mast cell activation syndrome and mastocytosis: initial treatment options and long-term management. <i>J Allergy Clin Immunol Pract</i>. 2019;7(4):1097-1106. doi:10.1016/j.jaip.2019.02.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cromolyn-sodium-cromoglicate-systemic-pediatric-drug-information/abstract-text/30961835/pubmed" id="30961835" target="_blank">30961835</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Cromolyn Sodium (oral solution) [prescribing information]. Mason, OH: Prasco Laboratories; December 2011.</div>
</li>
<li>
<div class="reference">
                  Gastrocrom (cromolyn) [prescribing information]. Somerset, NJ: Meda Pharmaceuticals; October 2018.</div>
</li>
<li>
<div class="reference">
                  Gastrocrom liquid (cromolyn) [prescribing information]. Somerset, NJ: Meda Pharmaceuticals; April 2015.</div>
</li>
<li>
<div class="reference">
                  Nalcrom (cromolyn sodium) [product monograph]. Laval, Quebec, Canada: Sanofi-Aventis Canada Inc; December 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33524167">
<a name="33524167"></a>Pardanani A. Systemic mastocytosis in adults: 2021 update on diagnosis, risk stratification and management. <i>Am J Hematol</i>. 2021;96(4):508-525. doi:10.1002/ajh.26118<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cromolyn-sodium-cromoglicate-systemic-pediatric-drug-information/abstract-text/33524167/pubmed" id="33524167" target="_blank">33524167</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4403844">
<a name="4403844"></a>Walter SR, Evans ME, Richard AJ, et al. The fate of disodium cromoglycate in man. <i>J Pharm Pharmacol. </i>1972;24:525-531.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cromolyn-sodium-cromoglicate-systemic-pediatric-drug-information/abstract-text/4403844/pubmed" id="4403844" target="_blank">4403844</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. http://www.who.int/maternal_child_adolescent/documents/55732/en/.</div>
</li></ol></div><div id="topicVersionRevision">Topic 104823 Version 86.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
